Saxenda and Victoza are brand-name injection pens that contain the same active drug, liraglutide. Saxenda is used for weight management. Victoza is used to treat type 2 diabetes and to lower the risk ...

Saxenda (liraglutide) and Wegovy (semaglutide) are brand-name injections. They’re both prescribed for weight loss and long-term weight management. Saxenda is used daily, while Wegovy is used weekly.

Saxenda (liraglutide) is a prescription drug that’s used to help with weight loss. Saxenda can cause side effects that range from mild to serious. Examples include nausea, vomiting, and diarrhea.

On December 23, 2014, the FDA approved liraglutide, under the name Saxenda, to treat obesity, after having previously approved it under the name Victoza to treat type 2 diabetes mellitus (T2DM). As ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

The GLP-1 receptor agonist, which was first approved for adults in December 2014, is now a treatment option for adolescents with obesity ages 12-17 as adjunct to diet and exercise. More specifically, ...

More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major U.S ...

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with ...